Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer

• Main Authors: Hsuan‐Chen Liu (Author), Simone Capuani (Author), Andrew A. Badachhape (Author), Nicola Di Trani (Author), Daniel Davila Gonzalez (Author), Robin S. Vander Pol (Author), Dixita I. Viswanath (Author), Shani Saunders (Author), Nathanael Hernandez (Author), Ketan B. Ghaghada (Author), Shu‐Hsia Chen (Author), Elizabeth Nance (Author), Ananth V. Annapragada (Author), Corrine Ying Xuan Chua (Author), Alessandro Grattoni (Author)
• Format: Book
• Published: Wiley, 2023-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Immune checkpoint inhibitors (ICI), pembrolizumab and atezolizumab, were recently approved for treatment‐refractory triple‐negative breast cancer (TNBC), where those with Programmed death‐ligand 1 (PD‐L1) positive early‐stage disease had improved responses. ICIs are administered systemicall...